Home・Aktien・MannKind Corp

MannKind Corp

Geschlossen

BrancheGesundheitswesen

3.85 -2.04

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.81

Max

3.9699999999999998

Schlüsselkennzahlen
By Trading Economics
Einkommen	-671K -17M
Verkäufe	-22M 90M
KGV Branchendurchschnitt	140.5 68.51
EPS	-0.02
Gewinnspanne	-18.431
Angestellte	591
EBITDA	5M 2.5M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+110.94% upside

Dividenden
By Acuity
Nächstes Ergebnis	4. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	306M 1.2B
Vorheriger Eröffnungskurs	5.89
Vorheriger Schlusskurs	3.85

Nachrichtenstimmung

By Acuity

33%

67%

66 / 340 Ranking in Healthcare

MannKind Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

MannKind Corp Prognose

Kursziel

By TipRanks

110.94% Vorteil

12-Monats-Prognose

Durchschnitt 8.29 USD 110.94%

Hoch 13 USD

Tief 4.75 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für MannKind Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für MannKind Corp – Dist abgegeben haben.

Stimmung

By Acuity

66 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.